Cellectar BioSciences News

Buy Rating on Cellectar Biosciences Backed by Strong Clinical Data and Promising Drug Pipeline

TipRanksMay 16 02:10

Buy Rating on Cellectar Biosciences Backed by Promising Drug Candidate and Solid Financials

TipRanksMar 29 03:31

Analysts Conflicted on These Healthcare Names: Cellectar Biosciences (CLRB), MiMedx Group (MDXG) and Marinus (MRNS)

TipRanksMar 28 19:55

Cellectar Biosciences Analyst Ratings

BenzingaMar 28 19:35

Buy Rating Affirmed for Cellectar Biosciences on Strong Clinical Results and Acquisition Potential

TipRanksMar 5 01:00

Cellectar Biosciences Analyst Ratings

BenzingaMar 5 00:45

Roth MKM Reiterates Buy on Cellectar Biosciences, Maintains $20 Price Target

BenzingaMar 5 00:45

Analysts Offer Insights on Healthcare Companies: Cellectar Biosciences (CLRB), Ionis Pharmaceuticals (IONS) and CVRx (CVRX)

TipRanksJan 23 03:51

Analysts Offer Insights on Healthcare Companies: Cellectar Biosciences (CLRB) and Seres Therapeutics (MCRB)

TipRanksJan 10 01:00

Oppenheimer Boosts Price Target on Cellectar Biosciences to $11 From $8, Maintains Outperform Rating

MT NewswiresJan 9 21:46

Buy Rating Backed by Pivotal Trial Catalyst and Novel Drug Delivery Platform for Cellectar Biosciences

TipRanksJan 5 01:35

Buy Rating on Cellectar Biosciences: Promising Clinical Study, Fast Track Designation and Strong Financial Position

TipRanksNov 4, 2023 02:06

Oppenheimer Remains a Buy on Cellectar Biosciences (CLRB)

TipRanksNov 3, 2023 20:14

Maxim Group Sticks to Their Buy Rating for Cellectar Biosciences (CLRB)

TipRanksSep 6, 2023 23:45

Maxim Group Keeps Their Buy Rating on Cellectar Biosciences (CLRB)

TipRanksMay 6, 2023 02:47

Oppenheimer Adjusts Cellectar Biosciences Price Target to $10 From $11, Maintains Outperform Rating

MT NewswiresMay 5, 2023 21:49

Maxim Group Keeps Their Buy Rating on Cellectar Biosciences (CLRB)

TipRanksMar 11, 2023 03:50

Maxim Group Keeps Their Buy Rating on Cellectar Biosciences (CLRB)

TipRanksMar 2, 2023 01:40

Oppenheimer Adjusts Cellectar Biosciences Price Target to $12 From $47, Maintains Outperform Rating

MT NewswiresNov 4, 2022 22:53

Cellectar Biosciences Analyst Ratings

Benzinga Analyst RatingsNov 4, 2022 18:33